# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE

A. 510(k) Number: K052124   
B. Purpose for Submission: Clearance of a new device   
C. Analyte: Lupus Anticoagulant   
D. Type of Test: Clotting   
E. Applicant: American Diagnostica   
F. Proprietary and Established Names: Acticlot $\textsuperscript { \textregistered }$ dPT™   
G. Regulatory Information: 1. Regulation section: 21 CFR 864.7750 2. Classification: Class II 3. Product Code: GJS 4. Panel: 81 Hematology

# H. Intended Use:

1. Intended use(s): The ACTICLOT $\textsuperscript { \textregistered }$ dPT $\textsuperscript { \textregistered }$ is an in vitro diagnostic assay intended for the qualitative determination of Lupus Anticoagulants (LA) in human plasma.   
2. Indication(s) for use:   
3. Special condition for use statement(s):   
4. Special instrument Requirements:

# I. Device Description:

The ACTICLOT $\textsuperscript { \textregistered }$ dPT™ is a reagent kit. It has three reagents that are used selectively for a screening protocol and a confirmatory protocol. LA Buffer™ is used with dPT™ Activator for the screening protocol. LA Phospholipid™ is used with dPT™ Activator for the confirmatory protocol.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DVVtest $\textsuperscript { \textregistered }$ and DVVconfirm $\textsuperscript { \textregistered }$   
2. Predicate K number(s): K940490

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the qualitativedetermination of lupusanticoagulants (LA) inhuman plasma.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SampleRequirements</td><td rowspan=1 colspan=1>Citrated plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>Differences</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Clotting assay (PT)</td><td rowspan=1 colspan=1>Clotting assay (PTT)</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>In the screening protocol,dPTTM Activator(recombinant tissue factor)and calcium is mixed withLA BufferTM to initiateclotting. Instrumentation isused to measure the clottime. IN the confirmatoryprotocol, the dPTTMActivator is mixed with theLA PhospholipidsTMreagent, andinstrumentation is used todetermine the clot time.</td><td rowspan=1 colspan=1>Russell&#x27;s Viper Venomreagent in the DVVtest isused to initiate clotting inplasma and theninstrumentation is used tomeasure the clot time. Forthe confirmation assay,Russell&#x27;s Viper VenomReagent and phospholipidsin the DVVconfirm is usedto initiate clotting and theninstrumentation is used tomeasure clot time.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

# L. Test Principle:

The ACTICLOT dPT is a coagulation assay that identifies the presence of LA in plasma. Clotting is initiated by activating the tissue factor (extrinsic) coagulation pathway with tissue factor in the presence of calcium ions. Tissue Factor binds to Factor VIla resulting in the activation of Factor IX and Factor X. Factor Xa converts prothrombin to thrombin which initiates clot formation by cleaving fibrinogen to fibrin. Activation of the tissue factor pathway bypasses the activation of the contact intrinsic pathway and excludes any interference from deficiencies of Factors XI and XII.

In the Screening Protocol, the patient plasma is mixed with the ACTICLOT LA Buffer" and ACTICLOT dPT Activator". The clot time is determined by semi-automated or automated methods. A positive result is indicated by a prolonged clot time relative to an established normal range, In the Confirmatory Protocol, the patient plasma is mixed with the ACTICLOT LA Phospholipids" and ACTICLOT dPT Activator. A positive result is indicated by a significant reduction of the clot time relative to the clot time in the screening protocol.

Plasmas are identified as possessing LA when both the Screening and Confirmatory Protocols are performed and both tests are positive.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: ACTICLOT dPT reagent precision studies were performed on two sites using LAtrol Normal Control, LAtrol™ Abnormal Control, and various coagulation analyzers: ACL $\textsuperscript { \textregistered }$ 300R centrifugal analyzer, $\mathrm { B C T @ }$ , MLA $\textsuperscript { \textregistered }$ 900C coagulation analyzer, and the STA Compact $\textsuperscript { \textregistered }$ . Testing involved multiple runs over several days. Results are as follows:

TABLE 2. Precision Study Results with ACTICLOT\* dPT™   
b. Linearity/assay reportable range   

<table><tr><td rowspan=1 colspan=1>CoagulationAnalyzer</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>dPTScreeningmean(sec)</td><td rowspan=1 colspan=1>Intra-AssayCV (%)</td><td rowspan=1 colspan=1>Inter-AssayCV (%)</td><td rowspan=1 colspan=1>dPTConfirm-atorymean(sec)</td><td rowspan=1 colspan=1>Intra-AssayCV (%)</td><td rowspan=1 colspan=1>Inter-AssayCV (%)</td></tr><tr><td rowspan=2 colspan=1>ACL® 300R</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>32.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>30.2</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>63.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>36.9</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=2 colspan=1>BCT®</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>47.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>89.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>61.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=2 colspan=1>MLA® 900C</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>27.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>27.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>30.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=2 colspan=1>STACompact®</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>40.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>39.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>77.9</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>46.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.8</td></tr></table>

c. Traceability (controls, calibrators, or method):

d. Detection limit:

e. Analytical specificity: Testing demonstrated interference with lipemic, icteric and hemolysed samples.

Testing demonstrated no interference from unfractionated heparin up to and including $1 . 0 \mathrm { U / m L }$ .

The ACTICLOT $\textsuperscript { \textregistered }$ dPT™ screening time may be prolonged in patients with congenital or acquired factor deficiencies. Eighteen known Factor Deficiency patient plasmas were tested with ACTICLOT^ dPT and none tested positive for LA "neat" and/or with a 1:1 mix with pooled normal plasma.

Plasmas from patients treated with Coumadin and other oral anticoagulants may have prolonged ACTICLOT $\textsuperscript { \textregistered }$ dPT™ screening and confirmatory clot times.

f. Assay cut-off:

2. Comparison studies:

a. A. Method comparison with predicate device:

ACTICLOT $\textsuperscript { \textregistered }$ dPT™ Method comparison studies were performed two sites. Patient samples were tested using ACTICLOT $\textsuperscript { \textregistered }$ dPT™ and DVVtest $^ \mathrm { \textregistered }$ and DVVconfirm $^ \mathrm { \textregistered }$ .

Site 1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>#samples LA pos withDVVtest® and DVVconfirm®</td><td rowspan=1 colspan=1>#samples LA neg withDVVtest® and DVVconfirm</td></tr><tr><td rowspan=1 colspan=1>#samples LA pos withACTICLOT® dPTTM</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>#samples LA pos withACTICLOT® dPTTM</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td></tr></table>

49 out of 54 samples were in agreement $( 9 0 . 7 \% )$

Site 2   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>#samples LA pos withDVVtest® and DVVconfirm®</td><td rowspan=1 colspan=1>#samples LA neg withDVVtest® and DVVconfirm</td></tr><tr><td rowspan=1 colspan=1>#samples LA pos withACTICLOT® dPTTM</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>#samples LA pos withACTICLOT® dPTTM</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47</td></tr></table>

78 out of 89 samples were in agreement $( 8 7 . 6 \% )$

b. Matrix comparison:

a. Clinical sensitivity:

23 prescreened LA positive samples were tested at two sites with the predicate device, the subject device, and a third commercially available aPTT sensitive LA test.

# Percent LA Positive Test Results from each of Three LA Tests

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ACTICLOT® dPTTMa</td><td rowspan=1 colspan=1>DVVtest®/DVVconfirmb</td><td rowspan=1 colspan=1>aPTT reagentb</td></tr><tr><td rowspan=1 colspan=1>Number of Samples thatTested LA Positive withOne LA Test / Numberof LA Positive Plasmas</td><td rowspan=1 colspan=1>18/23</td><td rowspan=1 colspan=1>18/23</td><td rowspan=1 colspan=1>19/23</td></tr><tr><td rowspan=1 colspan=1>Percent LA Positive</td><td rowspan=1 colspan=1>78.3%</td><td rowspan=1 colspan=1>78.3%</td><td rowspan=1 colspan=1>82.6%</td></tr></table>

(a) Assays were performed using the ACL 300R coagulation analyzer, (b) Assays were performed using the Sysmex\*CA-1500 coagulation analyzer.

b. Clinical specificity: c. Other clinical supportive data (when a and b are not applicable):

4. Clinical cut-off:

5. Expected values/Reference range:

<table><tr><td rowspan=1 colspan=1>CoagulationAnalyzer</td><td rowspan=1 colspan=1>ACL 300R(n=25)</td><td rowspan=1 colspan=1>BCT®(n=32)</td><td rowspan=1 colspan=1>CA7000(n=20)</td><td rowspan=1 colspan=1>MLA® 900C&lt;n=93</td><td rowspan=1 colspan=1>ST4 (n=25)</td><td rowspan=1 colspan=1>STACompact®(n=25)</td></tr><tr><td rowspan=1 colspan=1>Screening Time(sec)</td><td rowspan=1 colspan=1>34.4 + 4.5</td><td rowspan=1 colspan=1>51.2 + 7.8</td><td rowspan=1 colspan=1>38.8 + 8.8</td><td rowspan=1 colspan=1>26.7 + 4.8</td><td rowspan=1 colspan=1>38.4 + 4.2</td><td rowspan=1 colspan=1>36.6 + 5.9</td></tr><tr><td rowspan=1 colspan=1>ConfirmatoryTime( sec)</td><td rowspan=1 colspan=1>29.2 + 4.8</td><td rowspan=1 colspan=1>50.5 + 11.0</td><td rowspan=1 colspan=1>35.8±4.0</td><td rowspan=1 colspan=1>26.2 + 5.2</td><td rowspan=1 colspan=1>34.9 + 8.5</td><td rowspan=1 colspan=1>35.7 + 3.1</td></tr><tr><td rowspan=1 colspan=1>S/C Ratio</td><td rowspan=1 colspan=1>1.18 + 0.12</td><td rowspan=1 colspan=1>1.02 + 0.12</td><td rowspan=1 colspan=1>1.08 ±0.26</td><td rowspan=1 colspan=1>1.02 + 0.16</td><td rowspan=1 colspan=1>1.11 +0.19</td><td rowspan=1 colspan=1>1.03 ±0.09</td></tr></table>

# Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.